T1	Participants 24 69	adults with established rheumatoid arthritis:
T2	Participants 181 277	patients with disease modifying antirheumatic drug (DMARD) refractory rheumatoid arthritis (RA).
T3	Participants 318 406	714 patients who received etanercept in one of 7 initial trials or a longterm extension.
T4	Participants 441 484	581 patients who enrolled in the extension.
T5	Participants 500 650	714 patients enrolled in the initial trials, 581 (81%) enrolled in the extension, and 388 (54%) patients are continuing to receive etanercept therapy.
T6	Participants 1061 1119	356 patients who completed 6 years of etanercept treatment
T7	Participants 1274 1308	167 patients who completed Year 7.
T8	Participants 1556 1584	patients with RA in general.
